Favus, M., Emkey, R., Leite, M., Devogelaer, J.P., Rodriguez, J., Peverly, C., Kaur, S.A. (1997) Five-Year Treatment of Osteoporosis in Postmenopausal Women with Oral Alendronate: Effects on Bone Mass and Turnover and Safety. Journal of Bone and Mineral Research, 12, 189.

has been cited by the following article:

• TITLE: Bisphosphonates Zoledronate and Alendronate for the Management of Postmenopausal Osteoporosis

  AUTHORS: IsraaIsraa Ahmed Radwan, Nahed Sedky Korany, Bassant Adel Ezzat

  KEYWORDS: Bisphosphonates, Alendronate, Zoledronate, Postmenopausal Osteoporosis

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.7 No.5, May 10, 2018

  ABSTRACT: Bisphosphonates are among the most frequently used antiresorptive drugs for the management of postmenopausal osteoporosis. We review here two of the commonly used bisphosphonates zoledronate and alendronate.